|
|
| | RXFP2 agonist 2 Basic information |
| Product Name: | RXFP2 agonist 2 | | Synonyms: | RXFP2 agonist 2;Pyrazino[2,1-c][1,4]benzodiazepine-6,12(2H,11H)-dione, 8-[3,5-bis(trifluoromethyl)phenyl]-1,3,4,12a-tetrahydro-2-[2-[2-iodo-4-(trifluoromethoxy)phenoxy]acetyl]-, (12aS)- | | CAS: | 2971704-85-3 | | MF: | C29H19F9IN3O5 | | MW: | 787.37 | | EINECS: | | | Product Categories: | | | Mol File: | 2971704-85-3.mol |  |
| | RXFP2 agonist 2 Chemical Properties |
| Boiling point | 781.085±60.00 °C(Press: 760.00 Torr)(predicted) | | density | 1.807±0.10 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | | pka | 12.434±0.20(predicted) |
| | RXFP2 agonist 2 Usage And Synthesis |
| Uses | RXFP2 agonist 2 is a selective, orally active and allosteric RXFP2 agonist with an EC50 value of 0.38 μM. RXFP2 agonist 2 induces osteoblast mineralization. RXFP2 agonist 2 increases bone formation in female mice. RXFP2 agonist 2 has the potential for the research of osteoporosis[1]. | | in vivo | RXFP2 agonist 2 (10 mg/kg; p.o.; 3 times per week for 8 weeks) promotes bone formation in female mice[1]. | Animal Model: | 8-week-old WT C57BL/6J female mice[1] | | Dosage: | 3 mg/kg for i.v.; 10 mg/kg for p.o. | | Administration: | I.v. or p.o. | | Result: | Exhibited a half-life of between 4-6.5h depending on the route of administration, with no accumulation at 10mg/kg, and oral bioavailability around 25-31%. |
| Animal Model: | 8-week-old WT C57BL/6J female mice[1] | | Dosage: | 10 mg/kg | | Administration: | P.o.; 3 times per week for 8 weeks | | Result: | Increased bone formation in mouse with significantly increased in Tb.N and Tb.Th, and increased BV/TV and decreased Tb.Sp. |
| | References | [1] Esteban-Lopez M, et al. Discovery of small molecule agonists of the Relaxin Family Peptide Receptor 2. Commun Biol. 2022 Nov 4;5(1):1183. DOI:10.1038/s42003-022-04143-9 |
| | RXFP2 agonist 2 Preparation Products And Raw materials |
|